Cargando…

Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial

BACKGROUND: Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care. METHODS: We undertook a cluster-randomised equivalence trial in Jinja, Uganda. 44 geographical are...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaffar, Shabbar, Amuron, Barbara, Foster, Susan, Birungi, Josephine, Levin, Jonathan, Namara, Geoffrey, Nabiryo, Christine, Ndembi, Nicaise, Kyomuhangi, Rosette, Opio, Alex, Bunnell, Rebecca, Tappero, Jordan W, Mermin, Jonathan, Coutinho, Alex, Grosskurth, Heiner
Formato: Texto
Lenguaje:English
Publicado: Lancet Publishing Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806484/
https://www.ncbi.nlm.nih.gov/pubmed/19939445
http://dx.doi.org/10.1016/S0140-6736(09)61674-3
_version_ 1782176311408590848
author Jaffar, Shabbar
Amuron, Barbara
Foster, Susan
Birungi, Josephine
Levin, Jonathan
Namara, Geoffrey
Nabiryo, Christine
Ndembi, Nicaise
Kyomuhangi, Rosette
Opio, Alex
Bunnell, Rebecca
Tappero, Jordan W
Mermin, Jonathan
Coutinho, Alex
Grosskurth, Heiner
author_facet Jaffar, Shabbar
Amuron, Barbara
Foster, Susan
Birungi, Josephine
Levin, Jonathan
Namara, Geoffrey
Nabiryo, Christine
Ndembi, Nicaise
Kyomuhangi, Rosette
Opio, Alex
Bunnell, Rebecca
Tappero, Jordan W
Mermin, Jonathan
Coutinho, Alex
Grosskurth, Heiner
author_sort Jaffar, Shabbar
collection PubMed
description BACKGROUND: Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care. METHODS: We undertook a cluster-randomised equivalence trial in Jinja, Uganda. 44 geographical areas in nine strata, defined according to ratio of urban and rural participants and distance from the clinic, were randomised to home-based or facility-based care by drawing sealed cards from a box. The trial was integrated into normal service delivery. All patients with WHO stage IV or late stage III disease or CD4-cell counts fewer than 200 cells per μL who started antiretroviral therapy between Feb 15, 2005, and Dec 19, 2006, were eligible, apart from those living on islands. Follow-up continued until Jan 31, 2009. The primary endpoint was virological failure, defined as RNA more than 500 copies per mL after 6 months of treatment. The margin of equivalence was 9% (equivalence limits 0·69–1·45). Analyses were by intention to treat and adjusted for baseline CD4-cell count and study stratum. This trial is registered at http://isrctn.org, number ISRCTN 17184129. FINDINGS: 859 patients (22 clusters) were randomly assigned to home and 594 (22 clusters) to facility care. During the first year, 93 (11%) receiving home care and 66 (11%) receiving facility care died, 29 (3%) receiving home and 36 (6%) receiving facility care withdrew, and 8 (1%) receiving home and 9 (2%) receiving facility care were lost to follow-up. 117 of 729 (16%) in home care had virological failure versus 80 of 483 (17%) in facility care: rates per 100 person-years were 8·19 (95% CI 6·84–9·82) for home and 8·67 (6·96–10·79) for facility care (rate ratio [RR] 1·04, 0·78–1·40; equivalence shown). Two patients from each group were immediately lost to follow-up. Mortality rates were similar between groups (0·95 [0·71–1·28]). 97 of 857 (11%) patients in home and 75 of 592 (13%) in facility care were admitted at least once (0·91, 0·64–1·28). INTERPRETATION: This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care. FUNDING: US Centers for Disease Control and Prevention and UK Medical Research Council.
format Text
id pubmed-2806484
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Lancet Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28064842010-01-29 Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial Jaffar, Shabbar Amuron, Barbara Foster, Susan Birungi, Josephine Levin, Jonathan Namara, Geoffrey Nabiryo, Christine Ndembi, Nicaise Kyomuhangi, Rosette Opio, Alex Bunnell, Rebecca Tappero, Jordan W Mermin, Jonathan Coutinho, Alex Grosskurth, Heiner Lancet Articles BACKGROUND: Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care. METHODS: We undertook a cluster-randomised equivalence trial in Jinja, Uganda. 44 geographical areas in nine strata, defined according to ratio of urban and rural participants and distance from the clinic, were randomised to home-based or facility-based care by drawing sealed cards from a box. The trial was integrated into normal service delivery. All patients with WHO stage IV or late stage III disease or CD4-cell counts fewer than 200 cells per μL who started antiretroviral therapy between Feb 15, 2005, and Dec 19, 2006, were eligible, apart from those living on islands. Follow-up continued until Jan 31, 2009. The primary endpoint was virological failure, defined as RNA more than 500 copies per mL after 6 months of treatment. The margin of equivalence was 9% (equivalence limits 0·69–1·45). Analyses were by intention to treat and adjusted for baseline CD4-cell count and study stratum. This trial is registered at http://isrctn.org, number ISRCTN 17184129. FINDINGS: 859 patients (22 clusters) were randomly assigned to home and 594 (22 clusters) to facility care. During the first year, 93 (11%) receiving home care and 66 (11%) receiving facility care died, 29 (3%) receiving home and 36 (6%) receiving facility care withdrew, and 8 (1%) receiving home and 9 (2%) receiving facility care were lost to follow-up. 117 of 729 (16%) in home care had virological failure versus 80 of 483 (17%) in facility care: rates per 100 person-years were 8·19 (95% CI 6·84–9·82) for home and 8·67 (6·96–10·79) for facility care (rate ratio [RR] 1·04, 0·78–1·40; equivalence shown). Two patients from each group were immediately lost to follow-up. Mortality rates were similar between groups (0·95 [0·71–1·28]). 97 of 857 (11%) patients in home and 75 of 592 (13%) in facility care were admitted at least once (0·91, 0·64–1·28). INTERPRETATION: This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care. FUNDING: US Centers for Disease Control and Prevention and UK Medical Research Council. Lancet Publishing Group 2009-12-19 /pmc/articles/PMC2806484/ /pubmed/19939445 http://dx.doi.org/10.1016/S0140-6736(09)61674-3 Text en © 2009 Elsevier Ltd. All rights reserved. This document may be redistributed and reused, subject to certain conditions (http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0) .
spellingShingle Articles
Jaffar, Shabbar
Amuron, Barbara
Foster, Susan
Birungi, Josephine
Levin, Jonathan
Namara, Geoffrey
Nabiryo, Christine
Ndembi, Nicaise
Kyomuhangi, Rosette
Opio, Alex
Bunnell, Rebecca
Tappero, Jordan W
Mermin, Jonathan
Coutinho, Alex
Grosskurth, Heiner
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
title Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
title_full Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
title_fullStr Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
title_full_unstemmed Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
title_short Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
title_sort rates of virological failure in patients treated in a home-based versus a facility-based hiv-care model in jinja, southeast uganda: a cluster-randomised equivalence trial
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806484/
https://www.ncbi.nlm.nih.gov/pubmed/19939445
http://dx.doi.org/10.1016/S0140-6736(09)61674-3
work_keys_str_mv AT jaffarshabbar ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT amuronbarbara ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT fostersusan ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT birungijosephine ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT levinjonathan ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT namarageoffrey ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT nabiryochristine ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT ndembinicaise ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT kyomuhangirosette ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT opioalex ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT bunnellrebecca ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT tapperojordanw ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT merminjonathan ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT coutinhoalex ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT grosskurthheiner ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial
AT ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial